Biopharmaceuticals Pharmacovigilance in Rheumatic Diseases: Evolution and Perspective

Annett Mudida^*
*Correspondence: Annett Mudida, Department of Biopharmaceutical, Alborz University of Medical Sciences, Karaj, Iran, Email:

Introduction

Biopharmaceuticals have revolutionized the management of rheumatic diseases, offering targeted therapies that significantly improve patient outcomes. As the field of biopharmaceuticals expands, so does the need for robust pharmacovigilance systems to monitor their safety and efficacy. Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Given the unique complexities associated with biopharmaceuticals-such as their biological origin, mechanisms of action and patient-specific responses-the need for vigilant monitoring is paramount [1].

The landscape of rheumatic diseases, which include conditions such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Systemic Lupus Erythematosus (SLE), is characterized by chronic inflammation and often progressive damage to joints and other tissues. Traditional treatments have often been limited in effectiveness and associated with significant side effects. The advent of biopharmaceuticals, particularly biologics and biosimilars, has led to more personalized approaches in therapy. However, the innovative nature of these treatments introduces new challenges for pharmacovigilance, necessitating an evolution in strategies and methodologies to ensure patient safety [2].

Description

The journey of biopharmaceuticals in treating rheumatic diseases began in the late 20th century with the introduction of monoclonal antibodies (mAbs) and other biologics. The first biologic approved for rheumatoid arthritis was etanercept, followed by infliximab and adalimumab. These drugs target specific components of the immune system, particularly Tumor Necrosis Factor (TNF), leading to significant advancements in treatment outcomes for patients with previously refractory conditions. Agents like etanercept and infliximab block the action of TNF, a pro-inflammatory cytokine involved in the pathogenesis of several rheumatic diseases. Drugs targeting interleukins (e.g., IL-1, IL-6) modulate the inflammatory response and are effective in conditions like RA and systemic sclerosis. Rituximab, which depletes B-cells, has shown efficacy in refractory cases of RA and SLE. These targeted therapies have led to a paradigm shift in treatment approaches, improving both the quality of life and long-term outcomes for patients [3].

Pharmacovigilance plays a crucial role in ensuring that biopharmaceuticals are safe and effective post-marketing. Biopharmaceuticals possess distinct safety profiles that differ from traditional small-molecule drugs. Adverse effects can range from infusion reactions to serious infections due to immunosuppression. The long-term impact of these therapies remains under investigation, necessitating continuous monitoring. Regulatory bodies, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), mandate pharmacovigilance systems to ensure that biopharmaceuticals remain safe for public use. This includes the collection of adverse event reports, ongoing safety evaluations and risk management strategies. As patients are increasingly involved in their treatment decisions, there is a greater demand for transparency regarding the risks associated with biopharmaceuticals. A patient-centric approach in pharmacovigilance enhances trust and encourages adherence to treatment regimens [4].

The evolution of pharmacovigilance systems has led to the development of various strategies to enhance drug safety monitoring. Spontaneous Reporting Systems: Healthcare professionals and patients report adverse events voluntarily, providing valuable real-world data. Electronic Health Records (EHR) Integration of Electronic Health Records (EHR) with pharmacovigilance systems allows for more comprehensive data collection, enabling the identification of adverse events across diverse populations. These studies actively monitor safety and efficacy in a larger patient population, providing insights that may not have been captured in pre-approval clinical trials. Utilizing disproportionality analysis and Bayesian methods to assess the likelihood of adverse events associated with specific drugs. Emerging technologies are increasingly being used to enhance signal detection capabilities by analyzing vast datasets for patterns and trends. One of the most significant challenges is the underreporting of adverse events. Many healthcare providers may not recognize or report mild adverse events. Patients may be hesitant to report side effects, fearing it could impact their treatment. The potential for the development of antibodies against biopharmaceuticals can lead to reduced efficacy and increased adverse effects, complicating the interpretation of safety data. Populations: Variability in patient responses based on genetics, comorbidities and concurrent medications can influence safety profiles. Different countries have varying regulatory frameworks for pharmacovigilance, leading to challenges in global data collection and safety assessments. Harmonization of practices is needed to facilitate better monitoring and reporting across regions [5].

Conclusion

The evolution of pharmacovigilance in the realm of biopharmaceuticals for rheumatic diseases reflects a growing recognition of the importance of safety monitoring in the context of innovative therapies. As biopharmaceuticals continue to transform the treatment landscape for conditions like rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus, the need for vigilant pharmacovigilance systems becomes increasingly critical. The journey thus far has highlighted both achievements and challenges. Significant advancements in data collection methods, risk management strategies and signal detection capabilities have enhanced our understanding of the safety profiles of these complex therapies. However, ongoing challenges, such as underreporting and regulatory variability, must be addressed to ensure patient safety.

Looking ahead, the integration of real-world evidence, advances in technology, collaborative networks and increased patient engagement will play pivotal roles in shaping the future of pharmacovigilance. By fostering a culture of safety and accountability, the biopharmaceutical industry can continue to provide innovative solutions for the management of rheumatic diseases, ultimately improving patient outcomes and quality of life.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Scheinfeld, N. "A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab." J Dermatol Treat 15 (2004): 280-294.

   Google Scholar, Crossref, Indexed at

2. Oshima, Yasuo, Hiroshi Tsukamoto and Arinobu Tojo. "Association of hepatitis B with antirheumatic drugs: A case–control study." Mod Rheumatol 23 (2013): 694-704.]

   Google Scholar, Crossref, Indexed at

3. Tejera-Segura, Beatriz and Iván Ferraz-Amaro. "Biological therapy and neurological manifestations. What do we know?." Reumatol Clin 13 (2017): 102-106.

   Google Scholar, Crossref, Indexed at

4. Nikiphorou, Elena, Hannu Kautiainen, Pekka Hannonen and Juha Asikainen, et al. "Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data." Expert Opin Biol Ther 15 (2015): 1677-1683.

   Google Scholar, Crossref, Indexed at

5. Hoeltzenbein, Maria, Evelin Beck, Richa Rajwanshi and Carina Gøtestam Skorpen, et al. "Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data." Semin Arthritis Rheum 46 (2016): 238-245.

   Google Scholar, Crossref, Indexed at